Dexcom Reports Q3 2026 Revenue Growth of 11% Driven by U.S. Market Gains
Dexcom (DXCM) reported strong third-quarter 2026 results, with revenue reaching $1.3 billion, an 11% increase on both a reported and organic basis. The growth was primarily fueled by a 14% rise in U.S. revenue, driven by significant share gains across all customer segments, particularly within the type 2 diabetes market. Profitability also saw marked improvement, with non-GAAP gross margins expanding to 65.1% due to manufacturing efficiencies and lower freight costs. The company is successfully transitioning its user base toward the G7 extended-wear system, aiming for a 50% conversion rate in the U.S. by year-end. Clinical validation from the CONNECT study published in the New England Journal of Medicine provides strong evidence for broader reimbursement potential among type 2 non-insulin users. While management warned of temporary margin pressure in Q4 due to scaling the new Ireland manufacturing facility, Dexcom raised its full-year 2026 guidance for both revenue and margins.
Tickers: $DXCM
Topics: eps beat free cash flow gross margin expansion guidance upgrade revenue growth stock buyback